Tofacitinib improves enthesitis in patients with psoriatic arthritis regardless of severity or location at baseline, according to data published in Arthritis Research and Therapy. “Patients with ...

Participants' mean age was 56, and mean duration of psoriatic arthritis was 17 years. Mean tender and swollen joint counts were 2.5 and 1.1, respectively, while clinical enthesitis was present in 14%.

In patients with psoriatic arthritis, secukinumab and adalimumab demonstrated similar results regarding enthesitis resolution. Consistency was maintained across timepoints and measurement methods.

Approximately one quarter of patients with psoriatic arthritis (PsA) exhibited axial involvement (axial PsA). Enthesitis, inflammatory bowel disease, and HLA-B27 positivity were associated with an ...

Patients with psoriatic arthritis with a family history of psoriatic disease are diagnosed with psoriasis and psoriatic ...

Ixekizumab (IXE) demonstrated efficacy and safety for the treatment of juvenile psoriatic arthritis (JPsA) and enthesitis -related arthritis (ERA) through 16 weeks among pediatric patents ...

Home NICE Guidance Conditions and diseases Musculoskeletal conditions Arthritis Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590] ...

Psoriatic Arthritis: An Evaluation of Sex-based Differences —In a study from Israel, men with psoriatic arthritis (PsA) had a higher prevalence of enthesitis on ultrasound compared with female ...

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has introduced 19 treatment recommendations for peripheral arthritis, enthesitis (inflammation of the entheses ...

Suggested remit: To appraise the clinical and cost effectiveness of secukinumab within its marketing authorisation for treating enthesitis-related arthritis or juvenile psoriatic arthritis. This topic ...